The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Long-term follow-up of belantamab mafodotin plus pomalidomide and dexamethasone in myeloma: DREAMM-8
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the DREAMM-8 study (NCT04484623), which compared belantamab mafodotin plus pomalidomide and dexamethasone with pomalidomide, dexamethasone and bortezomib in previously treated multiple myeloma. Prof. Dimopoulos highlights that long-term follow-up of this study continues to show a significant improvement in the progression-free survival in favor of the belantamab combination. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The DREAMM-8 study is a prospective randomized trial which compared belantamab mafodotin with pomalidomide and dexamethasone versus the combination of pomalidomide, dexamethasone and bortezomib in previously treated patients with multiple myeloma with one to three prior lines of therapy. The long-term follow-up of this study continues to show a significant improvement in the progression-free survival in favor of the belantamab combination with a median PFS of 32 months and with a trend for an overall survival benefit...
The DREAMM-8 study is a prospective randomized trial which compared belantamab mafodotin with pomalidomide and dexamethasone versus the combination of pomalidomide, dexamethasone and bortezomib in previously treated patients with multiple myeloma with one to three prior lines of therapy. The long-term follow-up of this study continues to show a significant improvement in the progression-free survival in favor of the belantamab combination with a median PFS of 32 months and with a trend for an overall survival benefit. The eye toxicity can be mitigated by giving the drug at less frequent intervals and by reducing the dose.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
